- Home
- ZBAI vs QNRX Comparison
ZBAI vs QNRX Comparison
Compare ZBAI & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZBAI | QNRX |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8M | 10.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZBAI | QNRX |
|---|---|---|
| Price | $6.66 | $12.25 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.7K | ★ 154.3K |
| Earning Date | 11-13-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,200,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 44.00 | N/A |
| 52 Week Low | $4.83 | $5.01 |
| 52 Week High | $45.00 | $41.80 |
Technical Indicators
Market Signals| Indicator | ZBAI | QNRX |
|---|---|---|
| Relative Strength Index (RSI) | 36.93 | 42.32 |
| Support Level | $6.58 | $11.48 |
| Resistance Level | $6.91 | $15.45 |
| Average True Range (ATR) | 0.25 | 2.60 |
| MACD | -0.00 | -1.05 |
| Stochastic Oscillator | 21.98 | 11.54 |
Price Performance
Historical ComparisonAbout ZBAI ATIF Holdings Limited Ordinary Shares
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.